Welcome to our dedicated page for X4 Pharmaceuticals SEC filings (Ticker: XFOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
X4 Pharmaceuticals, Inc. filings document a rare-disease biopharmaceutical issuer with commercial activity for XOLREMDI and development work around mavorixafor. Its 8-K reports cover operating and financial results, material agreements, restructuring actions, executive and board changes, and capital-structure updates involving common stock, pre-funded warrants, registration rights, and equity purchase arrangements.
Proxy materials describe shareholder voting matters, board composition, committee assignments, executive compensation, equity awards, and governance procedures. The filing record also includes disclosures tied to the company’s inducement and equity incentive practices, financing arrangements, and formal reporting of material corporate events.
X4 Pharmaceuticals, Inc. reported results of its annual stockholder meeting. Stockholders approved the Second Amended and Restated 2017 Equity Incentive Plan, adding 1,500,000 shares to the pool available for equity awards. As of March 13, 2026, there were 90,919,696 common shares outstanding and entitled to vote.
Three Class III directors—Gary J. Bridger, Ph.D., Françoise De Craecker, and Michael S. Wyzga—were elected to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 and approved, on a non-binding basis, the compensation of the named executive officers.
X4 Pharmaceuticals filed a shelf registration on Form S-3 to offer up to $300,000,000 of securities, including common stock, preferred stock, debt securities, warrants and/or units. The filing includes an at-the-market sales agreement with Jefferies to sell up to $75,000,000 of common stock.
The prospectus discloses that X4 has one approved product, XOLREMDI® (mavorixafor), and is conducting a global Phase 3 4WARD trial in chronic neutropenia targeting up to 176 patients with full enrollment aimed for the end of Q3 2026. The base prospectus and any prospectus supplement will specify terms and intended uses of proceeds.
X4 Pharmaceuticals reported a Q1 2026 net loss of $20.2 million, reversing a small profit a year earlier as prior-year one-time license revenue from Norgine did not repeat. Total revenue was $2.7 million, including $2.5 million of U.S. XOLREMDI product sales and $0.2 million from its Norgine license.
Research and development expenses were $15.5 million and general and administrative expenses were $6.9 million, both down sharply following 2025 restructuring. X4 ended March 31, 2026 with $233.7 million in cash, cash equivalents and short-term marketable securities and $75.0 million of Hercules term debt.
During the quarter, X4 continued enrolling its global Phase 3 4WARD trial of mavorixafor in chronic neutropenia. On April 29, 2026, after quarter-end, the European Commission granted marketing authorization for XOLREMDI capsules to treat patients with WHIM syndrome in the European Union.
X4 Pharmaceuticals files its 2025 Annual Report on Form 10-K. The company describes its business as a developer and commercializer of novel therapeutics for rare hematology diseases, with one FDA‑approved product, XOLREMDI® (mavorixafor), for WHIM syndrome.
Highlights include a 1‑for‑30 reverse stock split, $253.0 million in cash, cash equivalents and marketable securities as of December 31, 2025, net proceeds of $81.0 million from an August 2025 PIPE and $145.6 million from a fourth‑quarter 2025 public offering, and 90,919,696 shares outstanding as of March 12, 2026. The company is conducting the global Phase 3 4WARD trial in chronic neutropenia, targeting full enrollment of 176 patients in the third quarter of 2026 with top‑line data expected in the second half of 2027. The EMA’s CHMP adopted a positive opinion in February 2026, with an EC final decision anticipated in the second quarter of 2026.
X4 Pharmaceuticals, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 11, 2026. The agenda includes electing three Class III directors to serve until 2029, ratifying PricewaterhouseCoopers LLP as auditor for 2026, approving an amended 2017 Equity Incentive Plan that adds 1,500,000 shares for employee and director awards, and a non-binding advisory vote on executive pay. Stockholders of record on March 13, 2026, when 90,919,696 common shares were outstanding, can vote online or by proxy. The proxy describes board structure, committee responsibilities, governance policies, and how compensation and equity awards are determined.
X4 Pharmaceuticals outlines a major transition in its annual report for the year ended December 31, 2025. The company focuses on rare hematology diseases, led by XOLREMDI (mavorixafor), which has accelerated FDA approval for WHIM syndrome and Fast Track status in chronic neutropenia.
X4 is running the pivotal 52‑week Phase 3 4WARD trial in chronic neutropenia, targeting 176 patients and aiming for top-line data in the second half of 2027. In August 2025, the company overhauled leadership and executed restructurings that cut headcount by about 65% to align around this program.
Funding was strengthened through an August 2025 PIPE that raised net $81.0 million and a fourth-quarter public offering with net proceeds of $145.6 million, leaving $253.0 million in cash, cash equivalents and marketable securities as of December 31, 2025. X4 also signed regional commercialization deals, including a €28.5 million upfront license with Norgine and distribution agreements in Europe, MENA, and China, while a positive EMA opinion for WHIM is under review by the European Commission.
X4 Pharmaceuticals, Inc. ownership update: Morgan Stanley, Morgan Stanley Investment Management Inc., and Inception Trust report substantial beneficial ownership of Common Stock.
The filing shows Morgan Stanley reporting units hold 8,884,338 shares with shared voting and dispositive power (reported 10.2% of the class). Morgan Stanley Investment Management Inc. is reported with 8,884,304 shares (10.2%) and Inception Trust with 4,518,236 shares (5.2%). Signatories include authorized representatives for the three filers, dated 03/06/2026.
X4 Pharmaceuticals, Inc. received an amended Schedule 13G/A from Biotechnology Value Fund–affiliated entities and Mark N. Lampert reporting a significant but sub‑5% passive stake. As of December 31, 2025, the group may be deemed to beneficially own 3,411,993 common shares, or about 3.9% of the company.
The position includes Pre-Funded Common Stock Purchase Warrants exercisable for 1,178,251 shares, with a token exercise price of $0.001 per share and no expiry, subject to a 9.99% ownership cap. The filers certify the securities are not held to change or influence control of X4 Pharmaceuticals.
Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund, and Ortav Yehudai report beneficial ownership of 5,227,222 shares of X4 Pharmaceuticals common stock as of December 31, 2025, representing 5.8% of the company.
The position includes 2,571,478 shares held directly and 2,655,744 shares underlying prefunded warrants, all held through Trails Edge Biotechnology. The ownership percentage is based on 87,436,688 shares outstanding as of October 31, 2025. The filers certify the holdings are not for the purpose of changing or influencing control of X4 Pharmaceuticals.
X4 Pharmaceuticals, Inc. disclosed that a group of Bain Capital Life Sciences funds and related entities collectively reported beneficial ownership of 8.41% of its common stock as of December 31, 2025. This total includes 615,649 common shares, a pre-funded warrant for up to 7,047,216 shares, and additional warrants for up to 304,589 shares.
The warrants and pre-funded warrants are subject to Beneficial Ownership Blockers that prevent exercises if the group would exceed 9.99% ownership of common stock, or 4.99% in the case of the Class C warrants, immediately after exercise.